论文部分内容阅读
应用RT－PCR技术对31例初诊急性髓细胞白血病（AML）患者mdr1基因进行检测、发现mdr1表达率为41．94％；AML亚型中以M5的mdr1表达率最高，M3最低；mdr1表达与临床患者耐药发生率显著相关。同时应用一级相关单抗，采用碱性磷酸酶抗碱性磷酸酶方法分析了患者细胞免疫标记与mdr1表达及预后的关系，结果显示，CD34与mdr1协同表达者耐药发生率更高。提示进行mdr1基因表达检测的同时，观察CD34表达情况，可能对预测化疗效果有意义。
RT-PCR technique was used to detect the mdr1 gene in 31 newly diagnosed acute myeloid leukemia (AML) patients. The mdr1 expression rate was found to be 41.94%. The expression of mdr1 was highest in M5 and lowest in M3 in AML subtypes; The incidence of drug resistance in clinical patients was significantly correlated. At the same time, a primary monoclonal antibody was used and alkaline phosphatase anti-alkaline phosphatase method was used to analyze the relationship between the patient’s cellular immune markers and mdr1 expression and prognosis. The results showed that the co-expression of CD34 and mdr1 was higher in the incidence of drug resistance. The detection of mdr1 gene expression and the observation of the expression of CD34 may be of significance in predicting the effect of chemotherapy.